Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664457 | 0.88 | HRH4 (0.40) | IDO1HRH4HRH3 | |
| SCHEMBL6667210 | 0.86 | HRH3 (0.41) | IDO1MAOBHRH4HRH3 | |
| SCHEMBL6692241 | 0.82 | HRH3 (0.43) | IDO1HRH4HRH3 | |
| SCHEMBL6660593 | 0.78 | HRH4 (0.42) | HRH4HRH3 | |
| SCHEMBL6666981 | 0.77 | HRH3 (0.40) | IDO1SCN8AHRH4HRH3 | |
| SCHEMBL6666000 | 0.76 | HRH3 (0.45) | HRH4HRH3 | |
| SCHEMBL6658270 | 0.74 | HRH3 (0.43) | IDO1HRH4HRH3 | |
| SCHEMBL6681815 | 0.74 | HRH3 (0.60) | HRH4HRH3 | |
| SCHEMBL6660501 | 0.74 | TDP1 (0.39) | IDO1SCN8AHRH4HRH3 | |
| SCHEMBL7561874 | 0.71 | IDO1 (0.55) | IDO1MAOBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446385-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2004-08-18 | — | — | EP | claimed |
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | claimed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | claimed |
| WO-2003040106-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2003-05-15 | — | — | WO | claimed |
| EP-1446385-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | disclosed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| WO-2003040106-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181479-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | IDO1 109/4885HTR6 44/4885DRD4 665/4885 |
| US-20040127718-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | IDO1 109/4885HTR6 44/4885DRD4 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.